Cited by 148Lipoproteins and Cardiovascular HealthLipid metabolism and disordersGenomics and Rare Diseases

Genetic testing in dyslipidemia: A scientific statement from the National Lipid Association

Brown, Emily E., Sturm, Amy C., Cuchel, Marina, Braun, Lynne T., Duell, P. Barton, Underberg, James A., Jacobson, Terry A., Hegele, Robert A.·2020·Journal of Clinical Lipidology

Abstract

The genetic basis for more than 2 dozen monogenic dyslipidemias has largely been defined. Genetic technologies, such as DNA sequencing, can detect both rare and common DNA variants underlying dyslipidemias, and these methods are increasingly available. Although patients with extreme abnormalities in low-density lipoprotein cholesterol, triglycerides, or high-density lipoprotein cholesterol may be considered for genetic testing, it is only in a minority of patients that the results will alter treatment or outcomes. Currently, there is potential clinical utility of genetic testing for familial hypercholesterolemia, familial chylomicronemia syndrome, sitosterolemia, lysosomal acid lipase deficiency, and a few other rare disorders, and this will increase the demand for reliable genetic diagnostic methods at lower cost. Clinical indications for genetic testing for most dyslipidemias are not clearly established and currently no guidelines exist. A shared decision-making model between the patient and the provider is essential as patient values and preferences play a very strong role. Potential benefits of genetic testing include providing a firm diagnosis in many cases, guiding optimal management and prevention strategies, advancing care strategies beyond currently available treatments, and contributing to overall scientific progress. Understanding the limitations and risks of genetic testing techniques is also important, as is careful interpretation of genetic test results to achieve the greatest benefit. Here we review laboratory methods, as well as technical, biological, clinical, and ethical implications and applications of genetic testing in dyslipidemias.

Integrity signals

Registry

Crossref · 10.1016/j.jacl.2020.04.011

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Familial chylomicronemia syndrome is caused by biallelic loss-of-function variants in LPL or in related genes needed for LPL activity.

    “The condition is caused by biallelic loss-of-function variants in LPL (encoding lipoprotein lipase) or in related genes needed for LPL activity. 10-12”
  • Loss of LPL activity results in a reduced ability to hydrolyze triglycerides in triglyceride-rich lipoproteins, leading to their accumulation in plasma and subsequent severe hypertriglyceridemia.

    “Loss of LPL activity results in a reduced ability to hydrolyze triglycerides in triglyceride-rich lipoproteins, such as intestinally derived chylomicrons and hepatically derived very-low-density lipoproteins, leading to their accumulation in plasma and subsequent severe hypertriglyceridemia. 10-12”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Brown, E. E., Sturm, A. C., Cuchel, M., Braun, L. T., Duell, P. B., Underberg, J. A., Jacobson, T. A., & Hegele, R. A.
Affiliations
  • Johns Hopkins University (US)
  • Geisinger Health System (US)
  • University of Pennsylvania (US)
  • Rush University (US)
  • Oregon Health & Science University (US)
  • NYU Langone Health (US)
  • Emory University (US)
  • Western University (CA)
Corresponding author
Hegele, Robert A.
Venue
Journal of Clinical Lipidology
Publisher
Elsevier BV
Published
2020-07
Volume
14
Issue
4
Pages
398-413
ISSN
  • 1876-4789 (ISSN-L)
  • 1933-2874
OpenAlex
W3021549637
Cited by
148
References
69
Citations by year
2026: 20 · 2025: 23 · 2024: 21 · 2023: 30 · 2022: 22 · 2021: 25 · 2020: 6 · 2019: 1
FWCI
23.99
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of clinical lipidology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Heart and Stroke Foundation of Canada (G-18-0022147)
  • Regeneron Pharmaceuticals
  • Canadian Institutes of Health Research
Topics
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
Keywords
genetic testing, dyslipidemia, familial hypercholesterolemia, familial chylomicronemia syndrome, sitosterolemia, lysosomal acid lipase deficiency, LDL cholesterol, triglycerides, HDL cholesterol, shared decision-making, genetic test result interpretation, genetic counseling, DNA sequencing
MeSH terms
Decision Making, Genetic Testing, Humans, Risk, Societies, Scientific, Dyslipidemias

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review